Navigation Links
Mount Sinai leads Consortium of Food Allergy Research with $29.9 million grant

Mount Sinai School of Medicine today announced that the National Institutes of Health (NIH) has renewed its funding of the Consortium of Food Allergy Research (CoFAR), providing an additional $29.9 million toward genetic research and the prevention and treatment of food allergy. Mount Sinai is the primary research site for CoFAR, leading seven other institutions around the country.

Under the renewed grant, Mount Sinai researchers will continue several clinical trials evaluating immunotherapies for peanut and egg allergy. In two of the studies, researchers are determining whether an extract of peanut protein under the tongue or ingesting increasing amounts of egg protein improves tolerance. In another trial, researchers administer gradually increased doses of peanut protein to patients in a suppository to treat the allergy. The Mount Sinai team will also initiate a new trial studying the use of a peanut protein patch applied to the skin to treat peanut allergy. CoFAR is also conducting an observational study that has enrolled more than 500 infants to determine what factors worsen or improve their allergies.

"We are excited about the progress we have made in understanding food allergy in children over the last five years," said Hugh Sampson, MD, Professor, Pediatrics, Chief, Division of Allergy & Immunology, Director of the Jaffe Food Allergy Institute, Mount Sinai School of Medicine and lead investigator on CoFAR. "With the renewal of this grant, we will expand our research and hopefully move closer toward ending the widespread impact of food allergy."

The grant will also fund new genetic research on eosinophilic gastrointestinal diseases (EGIDs), a new group of allergic diseases. According to the NIH, the most common EGID is eosinophilic esophagitis. The main symptoms in children include nausea, vomiting, and abdominal pain after eating. Three new CoFAR trial sites at Cincinnati Children's Medical Center Hospital, University of Colorado at Denver, and Children's Hospital of Philadelphia will conduct the research.

Dr. Sampson will remain principal investigator of the five original CoFAR sites: The Mount Sinai Medical Center, Duke University Medical Center, Johns Hopkins University, National Jewish Health in Denver, and University of Arkansas for Medical Sciences. CoFAR is currently enrolling patients for the trials evaluating treatment with peanut protein administered orally and through the skin patch.

Funding for CoFAR is provided by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases, components of NIH.


Contact: Mount Sinai Press Office
The Mount Sinai Hospital / Mount Sinai School of Medicine

Related medicine news :

1. The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen
2. Chicago Father and Son Team to Climb Mount Kilimanjaro for ShelterBox
3. AAU Big Mountain Jam Basketball Tournament To Be Played On SnapSports Flooring
4. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
5. Women who consume large amounts of tea have increased risk of rheumatoid arthritis
6. Albeo Releases Six New Surface Mount LED Lighting Fixtures
7. Green Drinks NYC and Green Mountain Energy Company Present Summer Bash at Solar One
8. The Mount Sinai Hospital Ranked in Top 25 of Best Children's Hospitals in Two Specialties by U.S. News & World Report
9. Mount Sinai researchers approaching universal treatment for all strains of influenza
10. Mountain Retreat for Women Whose Lives Have Been Touched by Cancer
11. Mount Sinai researchers move closer to a universal influenza vaccine
Post Your Comments:
(Date:11/25/2015)... OAK BROOK, Ill. (PRWEB) , ... November 25, ... ... sometimes larger and potentially more aggressive than those found on mammography, according to ... cases MRI findings of additional cancers not seen on mammography may necessitate a ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... factory direct sauna parts and accessories. , Sauna accessories help improve the bather ... style and personality. From basic styles for the purist looking for simplicity in ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
(Date:11/25/2015)... Crystal Lake, IL (PRWEB) , ... November 25, 2015 , ... ... pleased to announce a recent successful appellate decision obtained by Attorneys Francisco J. Botto ... the case Adcock v. Illinois Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw ... and learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. ... For 65 years, Brillianteen has been a treasured tradition for numerous families in ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... ATLANTA , Nov. 25, 2015 ... the first federal bellwether trial against Wright Medical ... relating to their Conserve metal-on-metal hip implant device, ... Christiansen.  Following a two week trial and three ... Conserve metal-on-metal hip device was defectively designed and ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... Endo International plc (NASDAQ: ENDP ) (TSX: ... and CEO, will discuss corporate updates at the 27 th ... York on Wednesday, December 2, 2015 at 1 ... Relations, and then the link to the event. Participants should ... to visit the site and download any streaming media software ...
Breaking Medicine Technology: